Avidity biosciences' del-zota demonstrated reversal of disease progression across key functional endpoints in explore44® and explore44-ole™ phase 1/2 trial in people living with dmd44

-- unprecedented improvement compared to baseline and natural history in multiple functional measures including time to rise from floor (ttr), 4-stair climb (4sc), performance of upper limb (pul) and 10-meter walk/run test (10mwrt) at approximately one year -- -- unprecedented rapid reduction in creatine kinase (ck) to near normal levels maintained over 16 months of follow-up and 25% increase of normal in dystrophin production, reflecting sustained muscle fiber protection -- -- avidity remains on track to submit biologics license application (bla) at year end 2025 for accelerated approval -- -- investor and analyst webcast event today at 8:00 a.m. et -- san diego , sept.
RNA Ratings Summary
RNA Quant Ranking